Biomotion Sciences Ordinary Shares Total Liabilities
Biomotion Sciences Ordinary Shares total liabilities. Based on the latest financial reports, Biomotion Sciences Ordinary Shares (SLXN) has total liabilities worth $4.20 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Biomotion Sciences Ordinary Shares liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Biomotion Sciences Ordinary Shares (2020–2025)
Total liabilities of Biomotion Sciences Ordinary Shares from 2020 to 2025. This chart illustrates how Biomotion Sciences Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data.
Biomotion Sciences Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Biomotion Sciences Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GACM Technologies Limited
NSE:GATECHDVR
|
India | Rs166.67 Million |
|
Accelerate Diagnostics Inc
NASDAQ:AXDX
|
USA | $84.60 Million |
|
East Star Resources PLC
LSE:EST
|
UK | GBX1.99 Million |
|
Ovoca Gold PLC
IR:OVXA
|
Ireland | €967.00K |
|
Superior Mining International Corp
V:SUI
|
Canada | CA$1.19 Million |
|
Hotel Fast SSE AB (publ)
ST:MAXENT-B
|
USA | Skr936.44 Million |
|
Magnum Goldcorp Inc
V:MGI
|
Canada | CA$144.78K |
|
Blockchaink2 Corp
V:BITK
|
Canada | CA$1.58 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Biomotion Sciences Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Biomotion Sciences Ordinary Shares total assets.
Liquidity & Leverage Metrics
Biomotion Sciences Ordinary Shares Total Liabilities Ratios Explained
Biomotion Sciences Ordinary Shares total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 95.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.99 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomotion Sciences Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomotion Sciences Ordinary Shares (2020–2025)
The table below shows the annual total liabilities of Biomotion Sciences Ordinary Shares from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.61 Million | -32.69% |
| 2024-12-31 | $6.85 Million | -60.42% |
| 2023-12-31 | $17.31 Million | +5.48% |
| 2022-12-31 | $16.41 Million | +3124.89% |
| 2021-12-31 | $508.92K | +69.98% |
| 2020-12-31 | $299.39K | -- |
About Biomotion Sciences Ordinary Shares
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for … Read more